Dosing & Uses
Hepatocellular Carcinoma
Pending FDA approval for first-line treatment of unresectable hepatocellular carcinoma in combination with camrelizumab
Next:
Pharmacology
Mechanism of Action
Inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
